IL301320B2 - Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia - Google Patents

Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Info

Publication number
IL301320B2
IL301320B2 IL301320A IL30132023A IL301320B2 IL 301320 B2 IL301320 B2 IL 301320B2 IL 301320 A IL301320 A IL 301320A IL 30132023 A IL30132023 A IL 30132023A IL 301320 B2 IL301320 B2 IL 301320B2
Authority
IL
Israel
Prior art keywords
compound
formulation
bfb
pharmaceutical formulation
subject
Prior art date
Application number
IL301320A
Other languages
English (en)
Hebrew (he)
Other versions
IL301320A (en
IL301320B1 (en
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of IL301320A publication Critical patent/IL301320A/en
Publication of IL301320B1 publication Critical patent/IL301320B1/en
Publication of IL301320B2 publication Critical patent/IL301320B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL301320A 2014-12-02 2015-11-30 Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia IL301320B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086691P 2014-12-02 2014-12-02
US201562248071P 2015-10-29 2015-10-29
PCT/US2015/062985 WO2016089766A1 (en) 2014-12-02 2015-11-30 Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Publications (3)

Publication Number Publication Date
IL301320A IL301320A (en) 2023-05-01
IL301320B1 IL301320B1 (en) 2024-07-01
IL301320B2 true IL301320B2 (en) 2024-11-01

Family

ID=54848909

Family Applications (4)

Application Number Title Priority Date Filing Date
IL301320A IL301320B2 (en) 2014-12-02 2015-11-30 Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
IL280052A IL280052B2 (en) 2014-12-02 2015-11-30 Preparations containing 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidine-4-yl)methyl)isoindolin-1-one for the treatment of schizophrenia
IL313572A IL313572A (en) 2014-12-02 2015-11-30 Preparations containing 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for the treatment of schizophrenia
IL252347A IL252347B (en) 2014-12-02 2017-05-17 Preparations containing 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidine-4-yl)methyl)isoindoline-1-one for the treatment of schizophrenia

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL280052A IL280052B2 (en) 2014-12-02 2015-11-30 Preparations containing 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidine-4-yl)methyl)isoindolin-1-one for the treatment of schizophrenia
IL313572A IL313572A (en) 2014-12-02 2015-11-30 Preparations containing 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for the treatment of schizophrenia
IL252347A IL252347B (en) 2014-12-02 2017-05-17 Preparations containing 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidine-4-yl)methyl)isoindoline-1-one for the treatment of schizophrenia

Country Status (26)

Country Link
US (7) US9458130B2 (enExample)
EP (2) EP4063357B1 (enExample)
JP (4) JP2018501217A (enExample)
KR (1) KR102620681B1 (enExample)
CN (2) CN111110677A (enExample)
AU (4) AU2015355226B2 (enExample)
BR (1) BR112017011555B1 (enExample)
CA (1) CA2968977A1 (enExample)
CL (2) CL2017001376A1 (enExample)
CO (1) CO2017005498A2 (enExample)
DK (1) DK3227273T3 (enExample)
EA (1) EA201791226A1 (enExample)
ES (2) ES2910528T3 (enExample)
HU (1) HUE058212T2 (enExample)
IL (4) IL301320B2 (enExample)
MX (1) MX385586B (enExample)
MY (1) MY185516A (enExample)
PE (1) PE20171646A1 (enExample)
PH (1) PH12017501007B1 (enExample)
PL (1) PL3227273T3 (enExample)
PT (1) PT3227273T (enExample)
SG (1) SG11201704332YA (enExample)
TW (1) TWI694069B (enExample)
UA (1) UA122780C2 (enExample)
WO (1) WO2016089766A1 (enExample)
ZA (1) ZA201703481B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301320B2 (en) 2014-12-02 2024-11-01 Minerva Neurosciences Inc Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN113694065A (zh) * 2016-05-25 2021-11-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CN107721988A (zh) * 2017-10-31 2018-02-23 无锡福祈制药有限公司 具有抗炎活性的异吲哚‑1‑酮类化合物
EP3840835A1 (en) 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
TWI841545B (zh) * 2018-12-12 2024-05-11 日商田邊三菱製藥股份有限公司 耐胃性控制釋放經口劑型
US12441701B2 (en) * 2019-06-28 2025-10-14 Tapi Czech Industries S.R.O. Solid state forms of roluperidone and salts thereof
IL298323B2 (en) 2020-05-20 2023-10-01 Univ Illinois A method for treating lysosomal storage disease using histatin peptides
CN116251078B (zh) * 2021-12-09 2025-12-19 河北以岭医药研究院有限公司 一种盐酸度洛西汀肠溶胶囊及其制备方法
EP4479049B1 (en) 2022-02-14 2025-12-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms
WO2026035878A1 (en) * 2024-08-07 2026-02-12 Nimbus Saturn, Inc. Hpk1 inhibitor formulations and methods of making the same
WO2026035872A1 (en) * 2024-08-07 2026-02-12 Nimbus Saturn, Inc. Hpk1 inhibitor formulations and methods of making the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ATE102482T1 (de) 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
EP0497843A4 (en) 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
FR2797643B1 (fr) 1999-08-17 2003-06-06 Rhodia Chimie Sa Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures
NZ521576A (en) * 2000-02-29 2005-06-24 Mitsubishi Pharma Corp Novel cyclic amide derivatives
WO2002076432A2 (en) 2001-03-26 2002-10-03 Novartis Ag Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
JP5281395B2 (ja) 2005-06-06 2013-09-04 メルク シャープ エンド ドーム リミテッド 統合失調症の治療用のｇｌｙｔ１阻害剤としてのシクロヘキサンスルホニル誘導体
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
WO2012012542A1 (en) * 2010-07-20 2012-01-26 Cyrenaic Pharmaceuticals, Inc. Methods of use of cyclic amide derivatives to treat schizophrenia
RU2746871C2 (ru) * 2010-07-20 2021-04-21 Сиренейк Фармасьютикалз Инк. Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2012227936A1 (en) * 2011-03-17 2013-10-17 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
IL301320B2 (en) 2014-12-02 2024-11-01 Minerva Neurosciences Inc Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN113694065A (zh) 2016-05-25 2021-11-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
EP3840835A1 (en) 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Also Published As

Publication number Publication date
DK3227273T3 (da) 2022-05-02
AU2020204286A1 (en) 2020-07-16
US20170042877A1 (en) 2017-02-16
PH12017501007B1 (en) 2024-07-03
EP4063357B1 (en) 2025-12-31
JP2018501217A (ja) 2018-01-18
US9730920B2 (en) 2017-08-15
IL252347B (en) 2021-01-31
MX385586B (es) 2025-03-18
PH12017501007A1 (en) 2017-12-18
US20210228561A1 (en) 2021-07-29
IL280052B1 (en) 2023-05-01
MX2017007065A (es) 2017-12-18
AU2021229240B2 (en) 2023-08-24
IL313572A (en) 2024-08-01
US20250195494A1 (en) 2025-06-19
PT3227273T (pt) 2022-04-06
EP3227273A1 (en) 2017-10-11
IL301320A (en) 2023-05-01
NZ770365A (en) 2023-10-27
EA201791226A1 (ru) 2017-09-29
IL301320B1 (en) 2024-07-01
PL3227273T3 (pl) 2022-05-30
IL280052A (en) 2021-03-01
ZA201703481B (en) 2023-12-20
TWI694069B (zh) 2020-05-21
AU2015355226A1 (en) 2017-06-08
US10799493B2 (en) 2020-10-13
CO2017005498A2 (es) 2017-09-20
CN111110677A (zh) 2020-05-08
US20200022968A1 (en) 2020-01-23
US9458130B2 (en) 2016-10-04
BR112017011555A2 (pt) 2018-01-09
IL280052B2 (en) 2023-09-01
EP4063357A1 (en) 2022-09-28
WO2016089766A1 (en) 2016-06-09
IL252347A0 (en) 2017-07-31
ES3065087T3 (en) 2026-05-04
BR112017011555B1 (pt) 2023-10-03
US10258614B2 (en) 2019-04-16
AU2020204286B2 (en) 2021-06-17
HUE058212T2 (hu) 2022-07-28
AU2015355226B2 (en) 2020-04-02
MY185516A (en) 2021-05-19
UA122780C2 (uk) 2021-01-06
JP2020172531A (ja) 2020-10-22
CL2017001376A1 (es) 2018-02-16
TW201632511A (zh) 2016-09-16
KR20170106310A (ko) 2017-09-20
AU2021229240A1 (en) 2021-10-07
PE20171646A1 (es) 2017-11-13
CA2968977A1 (en) 2016-06-09
ES2910528T3 (es) 2022-05-12
CN107567444A (zh) 2018-01-09
US20180153871A1 (en) 2018-06-07
KR102620681B1 (ko) 2024-01-04
US20230201184A1 (en) 2023-06-29
AU2023258386A1 (en) 2023-11-23
CL2021000044A1 (es) 2021-06-04
NZ732033A (en) 2023-10-27
JP2022105159A (ja) 2022-07-12
SG11201704332YA (en) 2017-06-29
AU2023258386B2 (en) 2025-10-23
JP7069253B2 (ja) 2022-05-17
JP2025004090A (ja) 2025-01-14
EP3227273B1 (en) 2022-02-09
US20160152597A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
AU2023258386B2 (en) Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN108883110A (zh) 使用食欲素-2受体拮抗剂治疗抑郁症的方法
US20110070319A1 (en) Bifeprunox doses for treating schizophrenia
NZ770365B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
NZ732033B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
BR122023014589B1 (pt) Usos de formulação farmacêutica que compreende di-hidrato de monocloridrato de 2-((1-(2-(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil) isoindolin-1-ona
EA040638B1 (ru) Фармацевтический состав, содержащий 2-((1-(2-(4-фторфенил)-2-оксоэтил)пиперидин-4-ил)метил)изоиндолин-1-он для лечения психоневрологического заболевания или расстройства сна, способ лечения психоневрологического заболевания или расстройства сна, таблетка и набор
US20250361243A1 (en) Compounds and Pharmaceutical Compositions Useful for Managing Sickle Cell Disease and Conditions Related Thereto